The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes (FAST 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05508061
Recruitment Status : Completed
First Posted : August 19, 2022
Last Update Posted : April 18, 2023
Sponsor:
Information provided by (Responsible Party):
Inreda Diabetic B.V.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The main objective is to determine the efficacy of Lyumjev (insulin) in a bi-hormonal reactive closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients with diabetes mellitus type 1. In addition, safety parameters, pharmacodynamics and AP-related parameters will be acquired.

This study is a multicenter, open-label, randomized, cross-over trial in 12 subjects. The subjects will be randomized to receive either Lyumjev or Humalog® for a 30-day study period and will then switch to the alternate insulin treatment after a wash-out period.


Condition or disease Intervention/treatment Phase
Type 1 Diabetes Drug: Insulin Lispro Cartridge [Lyumjev] Drug: Insulin Lispro Cartridge Not Applicable

Detailed Description:

Background of the study:

Inreda Diabetic B.V. (Goor, The Netherlands) developed a bi-hormonal reactive closed loop system to automate glucose regulation (artificial pancreas; AP) in patients with diabetes mellitus type 1. In the current CE-marked AP, Humalog® (Eli Lilly) is used as rapid-acting insulin. Currently, the ultra rapid-acting insulin Lyumjev (Eli Lilly) is available but has not yet been tested in combination with the AP of Inreda. Both are insulin lispro, but additions to the insulin lispro allow the insulin to act faster with a shorter duration. The hypothesis is that the combination of Lyumjev and the reactive AP system can decrease the time that glucose values are above range which can have a positive effect on glucose regulation.

Objectives of the study:

The main objective is to determine the efficacy of Lyumjev in the Inreda AP system. Secondary objectives are to assess safety parameters, differences in pharmacodynamics and AP-related outcomes comparing Lyumjev to Humalog®.

Study design:

This study is a multicenter, open-label, randomized, cross-over trial which will be performed in a free-living environment.

Study population:

The study population will comprise 12 subjects with diabetes type 1 using the AP system. Inclusion criteria are subjects from 18 to 75 years and treated with the Inreda AP system for at least 1 month.

Intervention:

The intervention includes the administration of Lyumjev by the Inreda AP system. The subject will be randomized to receive either Lyumjev or Humalog® during the first 30 days. After a wash-out period of 8 days using the standard insulin Humalog®, the subject will switch to the alternate treatment, again for a 30-day period. During the study periods, subjects have to keep a Wi-Fi access point with them.

Primary study parameters/outcome of the study:

Main parameter to express efficacy is the time above range (>10.0 mmol/l), which will be compared between Lyumjev and Humalog®.

Secondary study parameters/outcome of the study:

Safety will be expressed as the side effects of Lyumjev. Pharmacodynamics will be expressed in proportions of time spent in eu-/hypo-/hyperglycemia (%), median glucose value (mmol/l) and glycemic variability (% and interquartile range). These parameters will all be compared between Lyumjev and reference Humalog®.

AP-related outcomes will be expressed in daily administered dosage of insulin and glucagon (units), and the percentage of time that the closed loop algorithm is active (%).

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

Allocation by randomization:

  • Study period 1 (Humalog or Lyumjev)
  • Wash-out period (Humalog: standard therapy)
  • Study period 2 (other type of insulin than in Study period 1 (Humalog or Lyumjev))
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fully Automated Glycemic Control With Ultrarapid Insulin in a Bihormonal Closed Loop System in Patients With Type 1 Diabetes
Actual Study Start Date : October 19, 2022
Actual Primary Completion Date : March 16, 2023
Actual Study Completion Date : March 16, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Lyumjev (insulin lispro)
Administration of Lyumjev for a 30-day study period (dosage and frequency is patient-dependent)
 Drug: Insulin Lispro Cartridge [Lyumjev]
Administration of Lyumjev in combination with the AP system
Other Name: Lyumjev
Active Comparator: Humalog (insulin lispro)
Administration of standard used Humalog for a 30-day study period and 8-day wash-out period located between the two study periods (dosage and frequency is patient-dependent)
 Drug: Insulin Lispro Cartridge
Administration of Humalog in combination with the AP system (standard therapy)
Other Name: Humalog


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of time the glucose level is above 10 mmol/l for the study participants [ Time Frame: 68 days ]
    Time the glucose level is above range (>10 mmol/l) expressed as a percentage (%)


Secondary Outcome Measures :
  1. Safety parameters [ Time Frame: 30 days ]
    Side effects of Lyumjev

  2. Pharmacodynamic parameters: euglycemia [ Time Frame: 68 days ]
    Percentage of time the glucose level is between 3.9 and 10 mmol/l (%)

  3. Pharmacodynamic parameters: hypoglycemia [ Time Frame: 68 days ]
    Percentage of time the glucose level is below 3.9 mmol/l (%)

  4. Pharmacodynamic parameters: median glucose value [ Time Frame: 68 days ]
    Median of the glucose values (mmol/l)

  5. Pharmacodynamic parameters: standard deviation of glucose value [ Time Frame: 68 days ]
    Standard deviation of the glucose values (parameter required to determine the coefficient of variation)

  6. Pharmacodynamic parameters: mean glucose value [ Time Frame: 68 days ]
    Mean of the glucose values (parameter required to determine the coefficient of variation)

  7. Pharmacodynamic parameters: glycemic variability (CoV) [ Time Frame: 68 days ]
    Glycemic variability expressed as the coefficient of variation (CoV): standard deviation divided by the mean of the glucose values (%)

  8. Pharmacodynamic parameters: glycemic variability (IQR) [ Time Frame: 68 days ]
    Glycemic variability expressed as the interquartile range (IQR) (mmol/l)

  9. AP-related parameters: insulin usage [ Time Frame: 68 days ]
    Daily usage of insulin (units)

  10. AP-related parameters: glucagon usage [ Time Frame: 68 days ]
    Daily usage of glucagon (units)

  11. AP-related parameters: algorithm activity [ Time Frame: 68 days ]
    Percentage of time the algorithm is active (%)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with diabetes mellitus type 1;
  • Treated with the Inreda AP system for a minimum of 1 month;
  • Age between 18 and 75 years;
  • Willing and able to sign informed consent.

Since subjects are treated with the Inreda AP, the following inclusion criteria will be met:

  • Treated with sensor augmented pump (SAP) or CSII for a minimum of 6 months;
  • HbA1c < 97 mmol/mol;
  • BMI < 35 kg/m^2;
  • No use of acetaminophen, as this may influence the sensor glucose measurements.

Exclusion Criteria:

  • Impaired awareness of hypoglycemia (score ≥ 4) according to Gold and/or Clarke questionnaire;
  • Pregnancy and/or breastfeeding;
  • Use of oral antidiabetic agents;
  • Insulinoma;
  • Hypersensitivity reactions to Lyumjev or any of the excipients.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05508061


Locations
Layout table for location information
Netherlands
Rijnstate Hospital
Arnhem, Gelderland, Netherlands, 6815 AD
Slingeland Hospital
Doetinchem, Gelderland, Netherlands, 7009 BL
Hospital Gelderse Vallei
Ede, Gelderland, Netherlands, 6716 RP
Sponsors and Collaborators
Inreda Diabetic B.V.
Investigators
Layout table for investigator information
Principal Investigator: A. van Bon, MD, PhD Rijnstate Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Inreda Diabetic B.V.
ClinicalTrials.gov Identifier: NCT05508061    
Other Study ID Numbers: NL79588.091.22
First Posted: August 19, 2022    Key Record Dates
Last Update Posted: April 18, 2023
Last Verified: April 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Inreda Diabetic B.V.:
Ultra rapid-acting insulin
Lyumjev
Humalog®
Artificial pancreas (AP®)
 Bihormonal reactive closed loop system
Automated glucose regulation
Time above range
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
 Immune System Diseases
Insulin
Insulin, Globin Zinc
Insulin Lispro
Hypoglycemic Agents
Physiological Effects of Drugs